INCY · NASDAQ · STOCK
Incyte (INCY) Stock Analysis
$124.76
52W $81.09 – $132.60
68/100
$24.68B
15.0
0.77
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is INCY Bullish or Bearish?
Bullish.
Innellis AI committee rates Incyte (INCY) Buy with a composite score of 68/100
, based on 6 analysts with 83% agreement.
Last updated September 17, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +7.11 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -12.89 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock — Risk
- News sentiment is positive (+0.20 across 20 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 17, 2026
Overall Committee Score
68/100
Agreement
83%
Analysts
6
Conviction
High
Sector Rank
Top 0%
of 192 Healthcare peers
Value Analyst
bullish
65
/ 100 · High confidence
Classic value case: cheap on multiples with earnings power to back it up
+ ROE of 29.6% shows genuine earnings power backing the valuation
Growth Analyst
bullish
85
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 26.9% YoY -- genuine top-line momentum
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
64
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 20 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2514.55)
Investment Thesis Evolution
Committee score moved marginally from 67.9 to 67.9.
Comparing 2026-09-16 to 2026-09-17 (1 day apart).
Technical Analysis
RSI (14)
37.6
Neutral
MACD Histogram
-0.955
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$93.56
Resistance
$132.59
Bollinger %B
0.11
Inside Bands
Price vs Moving Averages
EMA 9
$123.72
Above
EMA 21
$124.10
Above
EMA 50
$120.63
Above
EMA 200
$106.32
Above
Fundamental Analysis
Valuation
88
Growth
91
Profitability
100
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
15.0×
P/B Ratio
3.85×
PEG Ratio
0.19
Dividend Yield
0.00%
52W High
$132.60
52W Low
$81.09
Quality & Growth
ROE
2489.9%
ROA
1849.2%
Gross Margin
9261.9%
Operating Margin
3157.2%
Revenue Growth YoY
—
Debt / Equity
0.01
AI Fundamental Assessment
P/E ratio of 15.0 (inexpensive relative to a 15-40x range); Price-to-book of 3.8x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 24.9%; Return on assets of 18.5%; Net margin of 27.7%; Gross margin of 92.6%; Current ratio of 4.66 (healthy short-term liquidity); Debt-to-equity of 0.01; Free cash flow per share is positive (9.58); Most recent quarter beat estimates by 44.1%; 2 consecutive earnings beats; EPS growth accelerating (+0.6% -> +70.7% QoQ); Average YoY EPS growth of 96.8%; Analyst estimates rising over recent quarters
Get the Full INCY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →